Funding Products and Clinical Phases

CipherBio Weekly Digest: Week of Jan 27 – Feb 2, 2022

This week’s funding events bring $1.77B in deals, $421M in Series A, 40 new companies added to CipherBio. Furthermore, lot of notable announcements in product clinical phases.

$1.77B
Deals

$421.0M
Series A

$249.5M
Series B

$638.3M
Later Rounds

$240.0M
M&A/IPOs

40
New Companies on CipherBio

Sign Up For Your Weekly Digest ➜

Top Deals Across Rounds

Septerna raises $100M in Series A round led by Third Rock Ventures. Also in Series A Enable Injections gets $215M led by Magnetar Capital. In Series B Athelas raises $132M led by General Catalyst. Patient 21 raises $142M in Series C round led by Target Global. Alto Pharmacy raises $200M in Series E led by Softbank Vision Fund. Maravai Life Sciences acquires MyChem for $240M. Akili Interactive Labs merger with a SPAC will net it up to $412M.

**See Investors Insights ➜**
Company	Round	Amount
Septerna	Series A	$100M
Enable Injections	Series A	$215M
Athelas	Series B	$132M
Patient 21	Series C	$142M
Alto Pharmacy	Series E	$200M
Maravai Life Sciences	Acquisition	$240M
Akili Interactive Labs	SPAC	$412M

This Week’s Lead Investors in Top Rounds

Lead investors this week are Third Rock Ventures, Magnetar Capital, General Catalyst, GV, Target Global, Softbank Vision Fund.

See Investors Insights ➜

Products and Clinical Phases

Viracta Therapeutics announces phase 1B/2 trial of Nana-Val in patients with advanced Epstein-Barr virus. Trevi Therapeutics completes enrollment in phase 2B/3 of Haduvio associated with chronic pruritus. Massachusetts-based Viridian Announces announces phase 1 trial of VRDN-002 for the treatment of thyroid eye disease. Arcutis starts their phase 3 trial of topical roflumilast foam in people with seborrheic dermatitis. Reviva Pharmaceuticals begins a phase 3 study of their product Brilaroxazine for the treatment of schizophrenia.

See All Clinical Insights ➜
Company	Product and Clinical Phase	Indications
Viracta Therapeutics	Nana-Val, Phase 1B/2	Epstein-Barr Virus, EBV Associated Lymphoma, Solid Tumors, Cancers and Other Neoplasms (NOS)
Viridian Announces	VRDN-002, Phase 1	Thyroid Eye Disease, Thyroid Disease, Eye Diseases
Aldeyra	Reproxalap, Phase 2	Dry Eye Diseases, Dry Eye
Trevi Therapeutics	Haduvio, Phase 2B/3	Pruritus, Peripheral Nervous System, Liver Disease
Arcutis Biotherapeutics	Roflumilast, Phase 3	Skin Disease, Seborrheic Dermatitis
Reviva	Brilaroxazine, Phase 3	Schizophrenia, Neurological Disorders, Psychiatric Disorders
Tracon Pharmaceuticals	TRC102, Phase 2	Lung Cancer, Mesothelioma
Aardvark Therapeutics	ARD 101, Phase 2	Metabolic Disorders, Inflammatory Disorders, Prader-Willi Syndrome

40 Life Science Companies Added

This week we added 40 new life science companies.

15 of 40 Companies
See Companies Insights ➜
Measure Labs	Resilience	Nude
Volta Labs	Susterre Technologies	Yamo Pharmaceuticals
Kula Bio	Censys	Iasis Molecular Science
Alpha10X	Zetta Genomics	Nuclera
Cropsy	Koning	ApolloMed